Treo Ventures, a venture capital fund focused on investments in high impact companies at the intersection of biology and technology in medical devices and digital health, announced the successful closing of its $128 million debut fund. The fund has a presence in Silicon Valley, CA and Dublin, Ireland, and will be supporting world class entrepreneurs across these geographies. Treo has been actively investing and building a portfolio of category defining companies including Hyalex Orthopedics, CVRx, ShiraTronics, Intuity Medical, NeoChord, and Noctrix Health.
Brad H. Vale, PhD, DVM, and Mudit K. Jain, MBA, PhD founded Treo in 2018 and Tracy Pappas joined the team in 2020. Leveraging the team's decades of healthcare venture investing experiences, Treo invests in companies that are developing and commercializing disruptive technologies to address major unmet healthcare needs. Areas of therapeutic interest include, but are not limited to, cardiovascular disease, neuro-mediated disorders, orthopedic and spinal diseases and injuries, metabolic disorders such as diabetes and obesity, respiratory, oncology and ophthalmic conditions. Treo backs companies with productive, domain-experienced, and stage-appropriate entrepreneurial teams. Additionally, Treo will invest in companies originated by NuXcel, a medical device accelerator, co-founded by Mudit Jain and Lynn Elliott, with a presence in Ireland and USA.
We're excited about our fundraising accomplishments and the portfolio we are building," said Mudit K. Jain, General Partner of Treo. "We've received tremendous support from our diverse set of limited partners that include a sovereign wealth fund, global medical device and pharmaceutical companies, and financial investors based in USA, Asia, and Europe. Our limited partners share our vision for developing and accelerating the delivery of clinically impactful, novel technologies. Brad Vale, General Partner of Treo, said, "Our goal is to build a portfolio of breakthrough technologies, addressing the biggest healthcare challenges of our time, while generating compelling investment returns."
Over the last 30 years, Treo's principals have established themselves as successful, highly respected venture capital investors, company builders, inventors, entrepreneurs, and senior leaders in the healthcare industry.
In addition to co-founding NuXcel and ShiraTronics, Mudit Jain brings over two decades of medical device industry experience across venture capital, company formation, R&D, and business development in companies such as Synergy Life Science Partners, Johnson & Johnson Development Corporation, and Guidant Corporation. Mudit currently serves on the boards of CVRx, ShiraTronics, Neochord, NuXcel, and Noctrix Health. Some of his prior investments/board responsibilities include Inspire Medical Systems, iRhythm Technologies, Neuspera, Aptus Endosystems (acqd. by Medtronic), CardioMEMS (acqd. by St. Jude Medical), and Impres Medical (acqd. by J&J).
Brad Vale has spent his entire 30-year career in the medical device field, including leading Johnson & Johnson Development Corporation, one of the largest corporate venture investors in the healthcare industry. He has invested in and/or served on the boards of over 30 companies, including Atrionix (acqd. by J&J), Indigo Medical (acqd. by J&J), Biosense (acqd. by J&J) and Nevro. Brad is also on the boards of Tramway Ventures, a technology seed fund, and Agilvax, an oncology biotech company, both in Albuquerque, New Mexico.
Tracy Pappas, a Partner at Treo, brings over 20 years of senior operational and finance experience in the medical device, venture capital, and technology industries to the investment team. Tracy held the position of Chief Financial Officer at Aptus Endosystems (acqd. by Medtronic), Synergy Life Science Partners, Partners for Growth and Scale Venture Partners. Tracy currently serves on the board of Noctrix Health.
About Treo Ventures
Founded in 2018 by Brad H. Vale, PhD, DVM, and Mudit K. Jain, PhD, Treo Ventures is a venture capital fund based in Silicon Valley, CA and Dublin, Ireland. The fund invests directly in private medical device and digital health companies that are developing breakthrough, disruptive technologies to address unmet healthcare needs. For more information, visit www.treovp.com
